IDSA Recommendations for Treating Visceral and Cutaneous ...
285
Description

IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS

Treating Visceral Leishmaniasis - Preferred Therapy:

 • Liposomal amphotericin B 2–4 mg/kg IV daily or

 • Liposomal amphotericin B interrupted schedule (e.g., 4 mg/kg on days 1–5, 10, 17, 24, 31, 38)

 • Achieve a total dose of 20–60 mg/kg

Chronic Maintenance Therapy for Visceral Leishmaniasis

Indication:

 • For patients with visceral leishmaniasis and CD4 count <200 cells/mm3

Preferred Therapy:

 • Liposomal amphotericin B 4 mg/kg every 2–4 weeks or

 • Amphotericin B Lipid Complex 3 mg/kg every 21 days

Treating Cutaneous Leishmaniasis

Preferred Therapy:

 • Liposomal amphotericin B 2–4 mg/kg IV daily for 10 days or interrupted schedule (e.g., 4 mg/kg on days 1–5, 10, 17, 24, 31, 38) to achieve total dose of 20–60 mg/kg or

 • Pentavalent antimony (sodium stibogluconate) 20 mg/kg IV or IM daily for 28 days

Chronic Maintenance Therapy for Cutaneous Leishmaniasis

 • May be indicated for immunocompromised patients with multiple relapses



#Leishmaniasis #Prevention #Treatment #management #opportunistic #infections #HIVAIDS #pharmacology
Contributed by

Dr. Gerald Diaz
@GeraldMD
Board Certified Internal Medicine Hospitalist, GrepMed Editor in Chief 🇵🇭 🇺🇸 - Sign up for an account to like, bookmark and upload images to contribute to our community platform. Follow us on IG:  https://www.instagram.com/grepmed/ | Twitter: https://twitter.com/grepmeded/
0 Comments

Related content